Publications by authors named "Alessia Bari"

Claim this Profile
P
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.
Rexhep Durmo, Stephane Chauvie, Federico Fallanca, Fabrizio Bergesio, Antonio Pinto, Alessia Bari

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study.
Alberto Bavieri, Maria E Nizzoli, Alessandra Tucci, Vittorio R Zilioli, Jacopo Olivieri, Alessia Bari

Hemasphere· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End of induction [F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.
Luca Guerra, Stephane Chauvie, Federico Fallanca, Fabrizio Bergesio, Luigi Marcheselli, Alessia Bari

Eur J Nucl Med Mol Imaging· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Maria E Nizzoli, Martina Manni, Chiara Ghiggi, Alessandro Pulsoni, Gerardo Musuraca, Alessia Bari

Hematol Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.
Alessia Bari, Chiara Gerardi, Eleonora Allocati, Agata Puzzovivo, Vitaliana De Sanctis

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.
Lydia Scarfò, Silvia Ferrari, Anna Maria Frustaci, Monica Tani, Alessia Bari

Blood Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi.
Luca Nassi, Vitaliana De Sanctis, Giacomo Loseto, Chiara Gerardi, Eleonora Allocati, Alessia Bari

Cancers (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma.
Samantha Pozzi, Alessia Bari, Martin Pecherstorfer, Sonia Vallet

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi.
Carla Minoia, Chiara Gerardi, Eleonora Allocati, Antonella Daniele, Vitaliana De Sanctis, Alessia Bari

Cancers (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature.
Martina Fanelli, Francesco Caputo, Krisida Cerma, Fabio Gelsomino, Alessia Bari

J Oncol Pharm Pract· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi.
Carla Minoia, Alessia Bari, Luca Nassi, Rita Banzi, Chiara Gerardi

Tumori· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatments.
Alessia Bari, Raffaella Marcheselli, Stefano Sacchi, Alessandro Re, Chiara Pagani

Ann Hematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Maria Christina Cox

Hematol Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.
Alessia Bari, Raffaella Marcheselli, Stefano Sacchi, Alessandro Re, Chiara Pagani

Ann Hematol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi.
Francesco Merli, Federica Cavallo, Flavia Salvi, Alessandra Tucci, Gerardo Musuraca, Alessia Bari

J Geriatr Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.
Raffaella Marcheselli, Antonella Franceschetto, Stefano Sacchi, Alessia Bari, Ilana Levy

Leuk Lymphoma· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
Jessika Bertacchini, Laura Mediani, Francesca Beretti, Marianna Guida, Aram Ghalali, Alessia Bari

J Cell Physiol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.
Alessia Bari, Luigi Marcheselli, Raffaella Marcheselli, Samantha Pozzi, Maria Christina Cox

Br J Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.
Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Maria Christina Cox

Hematol Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empathic attitudes among nursing students: a preliminary study.
Paola Ferri, Sergio Rovesti, Nunzio Panzera, Luigi Marcheselli, Alessia Bari

Acta Biomed· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, Chiara Monagheddu, Andrea Evangelista, Alessia Bari

Thromb Haemost· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Samantha Pozzi, Massimo Gentile, Stefano Sacchi, Raffaella Marcheselli, Alessandro Corso, Alessia Bari

Leuk Lymphoma· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Alessia Bari, Raffaella Marcheselli, Luigi Marcheselli, Isabel Alvarez, Samantha Pozzi

Acta Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.
Maria Cosenza, Monica Civallero, Stefania Fiorcari, Samantha Pozzi, Luigi Marcheselli, Alessia Bari

Cancer Biol Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
Stefano Sacchi, Raffaella Marcheselli, Alessia Bari, Gabriele Buda, Anna Lia Molinari

Haematologica· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis